A Clinical Investigation to Assess the Performance of Natural Rubber Latex Condoms in Couples
Primary Purpose
Control of Pregnancy, Prevention of Sexually Transmitted Infections
Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
NRL Condom
Sponsored by
About this trial
This is an interventional other trial for Control of Pregnancy
Eligibility Criteria
Inclusion Criteria:
- A male and a female subject aged: 18 - 60 years inclusive.
- All subjects must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months.
- All couples must be sexually active, and agree to have penile-vaginal intercourse with a frequency sufficient to meet protocol requirements (a minimum of 5 coital acts over 4 weeks).
- The female partner should use one other established highly effective form of non-barrier contraception, unless post-menopausal.
- Couples must agree not to use drugs or non-investigational devices that can affect sexual performance e.g. medication/medical devices used to treat erectile dysfunction.
Exclusion Criteria:
- Either partner is or becomes aware of an allergy or sensitivity to the ingredients of the test products, including the test or control condoms or any lubrication products provided.
- Either partner has a pre-existing skin condition (severe eczema/psoriasis) or systemic allergic reactions or as confirmed by the subject and physical examination.
- Either partner that needs to use condoms for a specific sexually transmitted infection (STI) protection e.g. discordance for Human Immunodeficiency Virus (HIV) or herpes.
- Subjects that have previous or planned genital surgery, that in the opinion of the Investigator would consider the subject unsuitable to participate in the clinical investigation e.g. laser for abnormal smear.
- Male partners that have known erectile or ejaculatory dysfunction.
- Either partner that requires to use/is using medication or preparations that are applied topically to the genitalia area or intravaginally other than that supplied for the investigation.
- A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the investigator, deems the partner unsuitable for the investigation.
- Any participant who has clinical symptoms or signs of a sexually transmitted diseases (STD) or HIV/AIDS or has a previous history of high risk behaviour as judged by the investigator.
- Female partner using medication which in the investigators opinion would affect vaginal mucosal secretion, such as Chlorpheniramine at any time in the 14 days (or 5 half-lives of the drug, whichever is longer) before first condom use.
- A male partner with abnormal penile anatomy that would, in the opinion of the investigator, affect the ability to keep the condom in place during intercourse.
- Either partner intends to continue to use antihistamines, anti-inflammatory drugs or pain killers for the duration of the investigation.
Sites / Locations
- Faculty of Medicine, Chulalongkorn University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
Test Condom: Thin NRL Condom
Reference condom A: Medium Thickness NRL Condom
Reference condom B: Thick NRL Condom
Arm Description
Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
Outcomes
Primary Outcome Measures
Compared clinical failure rate of condom use between the test condom group and the reference condom A group
Number of clinical failure events, defined in ISO 29943-1:2017, will be reported by participants.
Clinical failure rate is calculated as the number of condoms with at least 1 acute failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. A condom that experiences multiple clinical failure events only counts as a single clinical failure.
Secondary Outcome Measures
Compared clinical failure rate of condom use between the test condom group and the reference condom B group
Number of clinical failure events, defined in ISO 29943-1:2017, will be reported by participants.
Clinical failure rate is calculated as the number of condoms with at least 1 acute failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. A condom that experiences multiple clinical failure events only counts as a single clinical failure.
Compared clinical failure rate of condom use between the test condom group, the reference condom A group and reference condom B group
Number of clinical failure events, defined in ISO 29943-1:2017, will be reported by participants.
Clinical failure rate is calculated as the number of condoms with at least 1 acute failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. A condom that experiences multiple clinical failure events only counts as a single clinical failure.
Incidence of treatment-emergent adverse events and adverse device effects, defined in MEDDEV 2.7/3
Subject's experience on the use of each type of condoms [Acceptability and Tolerability]
Acceptability and tolerability as assessed by subject perceived questionnaires
Full Information
NCT ID
NCT03739190
First Posted
October 26, 2018
Last Updated
March 10, 2020
Sponsor
Reckitt Benckiser Healthcare (UK) Limited
1. Study Identification
Unique Protocol Identification Number
NCT03739190
Brief Title
A Clinical Investigation to Assess the Performance of Natural Rubber Latex Condoms in Couples
Official Title
A 3-way Cross-over, Multi-centre Clinical Investigation to Evaluate the Performance Rate of Natural Rubber Latex Condoms of Varying Thickness in Healthy Monogamous Couples
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
July 22, 2019 (Actual)
Primary Completion Date
December 27, 2019 (Actual)
Study Completion Date
December 27, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Reckitt Benckiser Healthcare (UK) Limited
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This investigation is designed to evaluate the performance rate of a new natural rubber latex (NRL) male condom.
Detailed Description
In this clinical investigation, a new NRL male condom (test condom) will be evaluated against two marketed NRL male condoms of varying thickness (condom A and condom B). This clinical investigation will also evaluate the in-use tolerance of the test and the two reference condoms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Control of Pregnancy, Prevention of Sexually Transmitted Infections
7. Study Design
Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Model Description
The condom types will be tested in a three-way cross-over design where couples will be randomised to use each of the three condom types in a defined order, according to the randomisation schedule.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Each condom will be contained within an individual foil packet on which all branding will been masked. All the condom types will be masked in the same manner and identical boxes will be used for the test and comparator condoms A and B.
Allocation
Randomized
Enrollment
470 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Test Condom: Thin NRL Condom
Arm Type
Experimental
Arm Description
Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
Arm Title
Reference condom A: Medium Thickness NRL Condom
Arm Type
Active Comparator
Arm Title
Reference condom B: Thick NRL Condom
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
NRL Condom
Intervention Description
A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
Primary Outcome Measure Information:
Title
Compared clinical failure rate of condom use between the test condom group and the reference condom A group
Description
Number of clinical failure events, defined in ISO 29943-1:2017, will be reported by participants.
Clinical failure rate is calculated as the number of condoms with at least 1 acute failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. A condom that experiences multiple clinical failure events only counts as a single clinical failure.
Time Frame
within 2 hours following each coital act for each condom use
Secondary Outcome Measure Information:
Title
Compared clinical failure rate of condom use between the test condom group and the reference condom B group
Description
Number of clinical failure events, defined in ISO 29943-1:2017, will be reported by participants.
Clinical failure rate is calculated as the number of condoms with at least 1 acute failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. A condom that experiences multiple clinical failure events only counts as a single clinical failure.
Time Frame
within 2 hours following each coital act for each condom use
Title
Compared clinical failure rate of condom use between the test condom group, the reference condom A group and reference condom B group
Description
Number of clinical failure events, defined in ISO 29943-1:2017, will be reported by participants.
Clinical failure rate is calculated as the number of condoms with at least 1 acute failure event (clinical slippage or clinical breakage) divided by the number of condoms used during intercourse, reported as a percentage. A condom that experiences multiple clinical failure events only counts as a single clinical failure.
Time Frame
within 2 hours following each coital act for each condom use
Title
Incidence of treatment-emergent adverse events and adverse device effects, defined in MEDDEV 2.7/3
Time Frame
16 weeks
Title
Subject's experience on the use of each type of condoms [Acceptability and Tolerability]
Description
Acceptability and tolerability as assessed by subject perceived questionnaires
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
A male and a female subject aged: 18 - 60 years inclusive.
All subjects must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months.
All couples must be sexually active, and agree to have penile-vaginal intercourse with a frequency sufficient to meet protocol requirements (a minimum of 5 coital acts over 4 weeks).
The female partner should use one other established highly effective form of non-barrier contraception, unless post-menopausal.
Couples must agree not to use drugs or non-investigational devices that can affect sexual performance e.g. medication/medical devices used to treat erectile dysfunction.
Exclusion Criteria:
Either partner is or becomes aware of an allergy or sensitivity to the ingredients of the test products, including the test or control condoms or any lubrication products provided.
Either partner has a pre-existing skin condition (severe eczema/psoriasis) or systemic allergic reactions or as confirmed by the subject and physical examination.
Either partner that needs to use condoms for a specific sexually transmitted infection (STI) protection e.g. discordance for Human Immunodeficiency Virus (HIV) or herpes.
Subjects that have previous or planned genital surgery, that in the opinion of the Investigator would consider the subject unsuitable to participate in the clinical investigation e.g. laser for abnormal smear.
Male partners that have known erectile or ejaculatory dysfunction.
Either partner that requires to use/is using medication or preparations that are applied topically to the genitalia area or intravaginally other than that supplied for the investigation.
A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the investigator, deems the partner unsuitable for the investigation.
Any participant who has clinical symptoms or signs of a sexually transmitted diseases (STD) or HIV/AIDS or has a previous history of high risk behaviour as judged by the investigator.
Female partner using medication which in the investigators opinion would affect vaginal mucosal secretion, such as Chlorpheniramine at any time in the 14 days (or 5 half-lives of the drug, whichever is longer) before first condom use.
A male partner with abnormal penile anatomy that would, in the opinion of the investigator, affect the ability to keep the condom in place during intercourse.
Either partner intends to continue to use antihistamines, anti-inflammatory drugs or pain killers for the duration of the investigation.
Facility Information:
Facility Name
Faculty of Medicine, Chulalongkorn University
City
Bangkok
Country
Thailand
12. IPD Sharing Statement
Learn more about this trial
A Clinical Investigation to Assess the Performance of Natural Rubber Latex Condoms in Couples
We'll reach out to this number within 24 hrs